Triamcinolone acetonide aqueous intranasal - Sanofi

Drug Profile

Triamcinolone acetonide aqueous intranasal - Sanofi

Alternative Names: Nasacort; Nasacort AQ; Nasacort® Allergy 24HR Nasal Spray; Triamcinolone acetonide water-based intranasal - Sanofi; XRG 5029

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Fluorinated steroids; Glucocorticoids; Pregnadienes; Small molecules
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Perennial allergic rhinitis; Seasonal allergic rhinitis

Most Recent Events

  • 10 Jul 2017 Sanofi completes in the phase III NASANIF trial for Perennial allergic rhinitis (NCT03317015)
  • 12 Jun 2015 Non-prescription aqueous intranasal triamcinolone acetonide licensed to PENDOPHARM for commercialisation in Canada
  • 11 Oct 2013 The US FDA approves Nasacort® as over-the-counter (OTC) product for treatment of Seasonal allergic rhinitis and Perennial allergic rhinitis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top